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ABSTRACT 
In the present work, formulation and evaluation of Sustained tablet of Divalproex sodium was carried out. In the project, dif ferent formulations 
of sustained release layer have been prepared. From above formulations best formulation of each sustained release was selected according to 
the dissolution profile. Divalproex sodium is soluble in 0.1 N NaOH, phosphate buffer pH 6.8, chloroform, methanol, ethanol (95%), and 
sparingly soluble in water. The absorbance maximum of the Divalproex sodium was found to be at 210 nm when scanned in between 200-400 
nm using methanol as well as phosphate buffer pH 6.8 solutions. All the characteristic peaks of Divalproex sodium were present in the spectrum 
of drug and excipient mixture, indicating compatibility between drug and excipients. In the present work SR tablets of Divalproex sodium were 
prepared by wet granulation method, using polymer like HPMC K4M for sustained release. Best formulations of was selected for  Divalproex 
sodium were subjected to hardness, weight variation, friability, drug content uniformity, in vitro drug release and drug polymer interaction. 
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1. INTRODUCTION 
Epilepsy is a common chronic neurological disorder that is 
characterized by recurrent unprovoked seizures. These 
seizures are  transient  signs  and/or  symptoms  due  to  
abnormal,  excessive  or  synchronous neuronal activity in 
the brain9Divalproex  sodium  dissociates  to  the  valproate  
ion  in  the  gastrointestinal tract. The mechanisms by which 
valproate exerts its therapeutic effects have not been 
established.1-3 It has been suggested  that  its  activity  in  
epilepsy  is  related  to  increased  brain  concentrations of 
Gamma‐Amino Butyric Acid (GABA). The absolute  
bioavailability  of Divalproate ER  tablets administered a  
single  dose  after  a  meal  was  approximately  90%  relative  
to  intravenous  infusion.  Formulation  of  Divalproex  
sodium  ER  tablets  expected to  reduce  Divalproex  sodium  
ER  is  used  by  patient  for  treatment  of chronic  epilepsy.4  
So  reduces  the  frequent  administration  of  dose  (twice  in  
a  day),  avoids  first  pass  metabolism,  improved  patient  
compliance,  maintain  therapeutic  action  by  administration  
of  a  single dose in a day 
For reasons discussed, a short half-life (i.e., ≤8 hours) is not 
necessarily synonymous with a short duration of action. In 
fact, even with rapidly distributed and reversibly acting 
drugs, the duration of action is dependent not only on half-
life but also on the size of the dose5. Additionally, it may be 
incorrect to assume that an even serum concentration profile 
is more beneficial than a profile consisting of peaks and 
troughs. Only well-controlled studies can determine which 
frequency of administration is optimal and whether any 
benefit can be expected from an extended-release 
formulation6-9. 
2. MATERIALS AND METHOD: 
2.1 Drug profile:  
Divalproex Sodium is a stable coordination compound 
comprised of sodium valproate and valproic acid with 
anticonvulsant and antiepileptic activities. Divalproex 
dissociates to the valproate ion in the gastrointestinal tract.10 
2.2 Description of drug molecule (Divalproex Sodium): 
 
(Fig 2.1: Chemical structure of Divalproex Sodium)10 
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2.3 Preparation of standard calibration curve of 
Divalproex Sodium11,12  
10 mg of drug was dissolved in 0.1 N NaOH and final volume 
was make up to 100 ml in 100 ml volumetric flask. The 
staock solution concentration was 100 mcg/ml obtained.  It 
was diluted with 0.1 N NaOH to obtain solution of  
Concentration range10 to 60 µg/ml. Absorbance of µg/ml 
solution was measured at 200-400  nm  by using of  
Shimadzu UV-1601 UV/Vis double beam spectrophotometer 
and 0.1 N NaOH  as reference standard. 
2.4 Melting point determination 
The Melting point of Divalproex Sodium was determined 
using open capillary method12. 
2.5 FTIR Spectra of pure drug 
Infrared spectroscopy analysis of Divalproex Sodium pure 
drug was performed by Fourier transfer infrared 
spectroscopy13. 
2.6 Differential scanning calorimetry 
The DSC of Tablet was recorded by differential scanning 
calorimeter equipped with a computerized data station14. 
2.7 Solubility Studies 
The solubility of Divalproex sodium was determined in 
distilled water, methanol, ethanol, acetone, chloroform and 
pH 6.8 phosphate buffer by shake flask method13. 
3. EVALUATION OF DIVALPROEX SODIUM POWDER 
BLEND (PRE-COMPRESSION PARAMETERS)14-19 
3.1 Angle of Repose 
The angle of repose of powder was determined by the funnel 
method. 
Tan θ=h/r ,  
Where θ = angle of repose, h = height of the cone, r radius of 
the cone base. 
3.2 Bilk Density 
A quantity of 10 g of powder from each formulation, 
previously lightly shaken to break any agglomerates formed 
was introduced into a 50 ml measuring cylinder. The bulk 
volume and mass of the powder was determined. The 
bulkdensity was calculated using following formula: 
Bulk density= Weight of granules/ Volume of granules 
3.3 Tapped density 
The measuring cylinder containing a known mass of blend 
was tapped for a fixed time. The minimum volume occupied 
in the cylinder and the mass of the blend was measured. The 
tapped density was calculated using the following formula:  
Tapped density= Weight of granules/ Volume of granules after 
100 tapping 
3.4 Tapped density 
The measuring cylinder containing a known mass of blend 
was tapped for a fixed time. The minimum volume occupied 
in the cylinder and the mass of the blend was measured. The 
tapped density was calculated using the following formula:  
Tapped density= Weight of granules/ Volume of granules after 
100 tapping 
3.5 Hausner’s ratio 
Hausner’s ratio value is less than 1.25 indicates good flow 
and greater than 1.5 indicates poor flow property which was 
calculated by using following formula:  
Hausner’s ratio = Tapped density/ Bulk density 
4. FORMULATION DESIGN: 
4.1 Preparation of sustained release formulation20-23:  
Accurately weighed Divalproex sodium and polymer and 
others ingredients were taken in mortar and pestle and 
mixed well. The powders were mixed with sufficient quantity 
for PVP K30 solution until wet mass formed. The cohesive 
mass obtained was passed though sieve # 16 and the 
granules were dried in a hot air oven at 500C for 20 min. The 
dried granules again passed through sieve # 22 to break the 
large lumps. Then granules were mixed with talc and 
magnesium stearate and compressed into 275 mg each tablet 
by adjusting hardness. 
 
Table 1: Formulation of Sustained Release (SR) Tablet  
S. No. Ingredients SF1 SF2 SF3 SF4 SF5 SF6 SF7 SF8 
1 Divalproex sodium 150 150 150 150 150 150 150 150 
2 
Lactose 
dehydrogenase 
52 45 37 52 45 37 52 45 
3 HPMC K4M 45 52 60 - - - 22 26 
4 HPMC K100M - - - 45 52 60 22.5 26 
5 
Microcrystalline 
cellulose 
20 20 20 20 20 20 20 20 
6 Magnesium stearate 2 2 2 2 2 2 2 2 
7 Talc 6 6 6 6 6 6 6 6 
8 Total 275 275 275 275 275 275 275 275 
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4.2 Evaluation of prepared formulations (Divalproex 
sodium SR tablet) 24-27 
The tablets prepared were evaluated for the following 
parameters: 
4.2.1 Weight Variation Test 
To study weight variation, 20 tablets of each formulation 
were weighted using electronic balance and the test was 
performed according to the official method. 
4.2.2 Hardness 
 The hardness of each batch of tablet was checked by using 
Monsanto hardness tester. 
4.2.3 Friability 
10 tablets were weighed and the initial weight of these 
tablets was recorded and placed in Roche friabilator and 
rotated at the speed of 25 rpm for 100 revolutions. 
Percentage friability was calculated by using the formula. 
   r a    t  = 
 n t ta  We  ht     na  We  ht
We  ht  n t a 
      
4.2.4 Tablet thickness 
Thickness of the tablet is important for uniformity of tablet 
size. Thickness was measured using Vernier Calipers. It was 
determined by checking the thickness of ten tablets of each 
formulation 
4.3 In Vitro dissolution studies 
The release rate Divalproex sodium SR tablet (n=3) was 
determined using The United States Pharmacopoeia (USP) 
XXIV dissolution testing apparatus II (paddle method). The 
dissolution test was performed using 900 ml of 0.1 N HCl, at 
37  0.5C and 75 rpm.28 
4.4 Accelerated stability study of the optimized batch29 
The tablets of batch F5 were packed in aluminum pouch and 
charged for accelerated stability studies at 40 °C and 75% 
RH for 3 months in a humidity jar. Drug dissolution profile of 
exposed sample was carried out. 
 
5. RESULT AND DISCUSSION:  
5.1 Standard Calibration Curve (CC) of divalproex Sodium in 0.1 N NaOH 
Table 2  Standard CC of Divalproex Sodium in 0.1 N NaOH 
Sr. No. Concentration 
(g/ml) 
Absorbance Average 
Absorbance 1 2 3 
1 
2 
3 
4 
5 
6 
10 
20 
30 
40 
50 
60 
 
0.128 
0.299 
0.402 
0.582 
0.778 
0.921 
 
0.124 
0.292 
0.404 
0.578 
0.769 
0.916 
0.132 
0.305 
0.401 
0.587 
0.783 
0.925 
0.128 
0.299 
0.402 
0.582 
0.778 
0.921 
 
Correlation Co-efficient  (R²) = 0.9944 
Absorbance(y) = 0.0159xconc - 0.0399 
 
 
Fig 5.1 Drug calibration curve in NaOH 0.1 N. 
5.2 Melting point  
The average melting point of pure drug is 2220C which is complies with Stander melting point of drug. 
5.3 Drug Excipient Compatibility Studies 
5.3.1 FTIR Study: 
y = 0.0159x - 0.0399 
R² = 0.9944 
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Fig 5.2 FTIR of Drug (Divalproex Sodium) 
 
Fig 5.3FTIR of Drug + HPMC 
 
Fig 5.4 FTIR of Drug +  Lactose Anhydrous 
 
Fig 5.5 FTIR of Drug + Microcrystalline cellulose 
5.3.2 Pre Compression Parameter of Formulation:                               
Table 3: Pre compress parameter 
S. No Parameters Values obtained 
1. Bulk density (gm/ml) 0.448± 0.007  
2. Tap density (gm/ml) 0.520±0.009  
3. Angle of repose (θ) 28º50’±0.121 
4. Carr's index 13.84 ± 0.21 
5. Hausner’s ratio 1.16 ± 0.003 
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5.3.3 Post Compression Parameter of Formulation: 
Table: 3 Physical Characteristics of powder blend 
Formulation 
code 
Angle of Repose(o) Bulk density Tap density Hausner ratio Carr's Index 
F1 20 o 28  ± 0.4568 0.374 ± 0.017 0.446± 0.002 1.16± 0.002 14.23± 0.532 
F2 21 o 22  ± 0.5449 0.352 ± 0.013 0.423± 0.003 1.17± 0.004 13.64± 0.368 
F3 20 o 17  ± 0.4225 0.380 ± 0.014 0.417± 0.001 1.18± 0.003 14.20± 0.398 
F4 20 o 14  ± 0.3326 0.360 ± 0.011 0.445± 0.004 1.17± 0.001 14.42± 0.215 
F5 21 o 09  ± 0.8547 0.358 ± 0.019 0.442± 0.004 1.16± 0.003 13.80± 0.309 
F6 20 o 18  ± 0.5226 0.353 ± 0.011 0.424± 0.002 1.15± 0.004 14.78± 0.408 
F7 20 o 54  ± 0.6548 0.364 ± 0.014 0.438± 0.006 1.15± 0.001 12.92± 0.554 
F8 22 o 16  ± 0.5547 0.376 ± 0.016 0.415± 0.002 1.16± 0.001 15.55± 0.612 
 
5.3.4 Dissolution profiles of formulation: 
Table 4 Cumulative Drug release (F-1 to F-8) 
Time (hr) F-1 F-2 F-3 F-4 F-5 F-6 F-7  F-8 
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0  0.0 
1 5.91 5.18 6.51 5.65 5.02 4.59 4.51  4.15 
2 9.23 8.99 7.26 6.22 6.11 5.89 5.36  5.13 
3 14.69 13.22 12.56 10.96 9.16 8.04 7.53  6.85 
4 19.02 18.57 17.26 15.38 14.04 12.19 11.33  10.34 
5 25.12 24.26 22.98 20.26 19.01 17.32 16.09  14.93 
6 30.32 29.54 27.52 25.53 23.99 22.05 20.54  18.32 
7 36.99 35.36 32.89 30.87 28.31 26.99 24.81  22.97 
8 41.94 39.81 38.06 36.04 34.33 32.87 30.86  28.56 
9 48.99 47.21 44.88 42.16 40.89 39.56 37.78  35.61 
10 53.89 52.69 50.55 48.78 46.65 45.13 43.72  41.91 
11 59.71 58.17 56.71 54.75 52.84 51.28 49.09  47.31 
12 64.22 62.95 61.13 59.59 57.78 56.11 54.84  52.79 
13 70.12 69.27 67.03 65.99 64.03 62.74 61.12  60.04 
14 78.99 77.13 74.65 72.22 71.04 69.33 67.99  65.46 
15 84.89 83.54 81.12 80.02 78.88 76.35 74.19  72.65 
16 89.91 88.15 87.11 86.65 85.12 84.89 83.68  82.21 
17 89.95 88.19 87.12 86.67 85.14 84.92 83.71  82.24 
 
 
 
Fig 5.6 Cumulative Release of Formulation F-1 to F-4 
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Fig 5.7 Cumulative Release of Formulation F-5 to F-8 
 
5.3.5 Content uniformity of sustained release tablets of 
Divalproex sodium: 
Formulation Code Content uniformity (%) 
F1         99±0.65  
F2 98±0.14 
F3 98±0.95 
F4 98±0.09 
F5 99±0.02 
F6 99±0.19 
F7 98±0.72 
F8 99±0.45 
 
6. CONCLUSION: 
The FTIR spectra showed that drug and polymer used in 
formulation of SR tablet are compatible with each other. The 
average melting point of pure drug is 2220C which is 
complies with Stander melting point of drug. The pre 
compress parameter result showed that powder blend of all 
formulations were good flow properties. The absorbance 
maximum of the Divalproex sodium was found to be at 210 
nm when scanned in between 200-400 nm using methanol 
as well as phosphate buffer pH 6.8 solutions. Calibration 
curve of Divalproex sodium in methanol measured at 210 
nm showed the slope of 0.0094 and regression coefficient of 
0.9995 was recorded. 
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